AI Article Synopsis
- Antiangiogenesis therapy helps treat colon cancer but often just relieves symptoms because cancer can come back.
- The study identifies that a specific group of tumor cells, marked by CD133(+), can survive this therapy.
- Researchers found a signaling pathway (involving PP2A, p38MAPK, MAPKAPK2, and Hsp27) that aids in the survival of these resistant cells, suggesting it could be a target for new treatments for colorectal cancer.
Article Abstract
Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133(+) population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2012.08.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!